Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Breast cancer treatment: perspectives on the oncolytic virus
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5409)
•••
Comment by Noteableon Sep 21, 2024 10:46am
109 Views
Post# 36234602

RE:RE:RE:RE:RE:RE:RE:RE:Breast cancer treatment: perspectives on the oncolytic virus

RE:RE:RE:RE:RE:RE:RE:RE:Breast cancer treatment: perspectives on the oncolytic virusONCY has sufficient positive data for an early Accelerated Approval in HR+HER2- mBC, with further positive data from ONCY's Phase 2 PDAC clinical trial being released sometime in Q4 2024, that will be entering into a CGAR adaptive Phase 2 clinical trial that also will be headed towards an Acclerated Approval. Nothing inept in that. So ONCY should be focused on both getting the HER2- mBC approval through as a first-off and simultaneously move ONCY into a Big Pharma company to achieve further development goals in additional indications and subsequent approvals. Then let Big Pharma more appropriately guide on development and approval timelines. They are much more knowledgeable and equipped to do that.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities